github.comSFT - The French Association of Translators - Any professional translator (who is paid for their work - in-house and self-employed language service providers as well as literary translators) may apply for membership in the French Association of Translators. Membership is open to all professional translators and interpreters who pay a periodical fee. ANTIMI - Associazione Nazionale dei Traduttori e degli Interpreti del Ministero dell’Interno - The National Association of Translators and Interpreters of the Ministry of Interior is a non-profit organisation that has existed since 2002 which aims to protect the personnel working in fields related to language in the Civil Administration of the Ministry. ASSITIG - Associazione Italiana Traduttori e Interpreti Giudiziari - The Italian Association of Legal Interpreters and Translators - AssITIG was first formed in Syracuse in 2010. The main purpose of the association is to promote professionalism among translators, and to provide fair representation in the justice system of those who are unable to speak and understand Italian. ATIA - Association of Professional Translators and Interpreters in Aquitaine - The Association of Professional Translators and Interpreters in Aquitaine has two main goals: to protect translation-related professionals and to ensure good communication between customers and professionals.
WASLI - World Association of Sign Language Interpreters - Set up in 2003 by 60 interpreters from 20 countries together with WFD (World Federation of the Deaf General) General Secretary, WASLI welcomes interpreters and interpreter association from all over the world. GALA - Globalization and Localization Association - World’s biggest non-profit organisation for the language industry, GALA provides resources for many companies around the world. Founded over 75 years ago, this non-profit association serves the interests of sworn and certified translators in Austria. AICE - Spanish Association of Conference Interpreters - AICE (Association of Conference Interpreters of Spain) is a non-profit professional organisation founded in 1968 specialising in conference interpreting in international events and meetings. It protects and represents the interests of literary, scientific and technical translators and interpreters. ELIA - European Language Industry Association - A not-for-profit organisation which aims to represent and promote the interests of the language industry in Europe by developing relationships with related bodies from all over the world. CETL - Centre européen de traduction littéraire (European Centre for Literary Translation) - The main purpose of this organisation is to offer post-graduate training in literary translation. This is especially important for Facebook Business Pages, which offer the most comprehensive view of your business, comparable to your website or Google Business Profile.
SRC:MixSentence, IDs:1CB5D976;485FA936;3AD5669B;AF24C528;430C4AF5;DE757C7F;4F45A2FE;24F2A662;99219F16;FC8C0D50;63624C40;F78D37A9;1F46BF33;4F03F29E;C54A2492;1FADB78C;0ECB4049;04EFBA12;6B520626;E73F66B8;EA15627F;F3096291;39C9A45B;CEC0943E;C0692D6E;48263096;62457DA4
If this is where clinical research is headed, that would be a terrible negative trajectory," he said. Dr. Topol - who drew attention last year with a finding that Celebrex and its competitor, Vioxx, appeared to raise the risk of heart attacks - said the Bextra studies did not include enough patients to justify drawing a broad conclusion. The average age of patients in the study, 23, did not represent the population likely to take the drug, he added. Yet through publication in the leading dental journal, the research helped Bextra's marketers shift attention away from the F.D.A.'s negative findings. Because of confidentiality rules, the F.D.A. cannot release any information about the earlier pain studies that failed to sway regulators. "Even though the study lacked some important proof, the real problem is that in the dental literature, this will be read," Dr. Topol said. "And dentists, who have to deal with trying to prevent or modulate pain, will be impressed." Judy Glova, a spokeswoman for Pharmacia, said the drug company stood behind the design and conclusions of the Scirex studies. Pharmacia was not trying to bypass the regulatory process, she said, adding that the company is in discussions with regulators to have Bextra approved for acute pain. Scirex executives did not return repeated phone calls. Editors at The Journal of the American Dental Association said the Scirex article was reviewed by at least three scientists. One reviewer, Dr. Paul A. Moore, an associate editor of the journal, said the study was "carefully designed and rigorously performed." But Dr. Moore said he would have recommended that the journal reject the paper had he known that Bextra was not approved for acute pain. The Bextra episode is just one example of the changing face of drug research. In the early 1990's, about 75 percent of the drug industry's clinical research dollars went to universities, according to a study by CenterWatch, a company that tracks clinical trials. By 2000, just 34 percent went to academic institutions, while the rest went to investigators working under the direction of either a private research firm like Scirex or a pharmaceutical company. Omnicom says it has no control over Scirex. "We have nothing to do with the design of clinical studies," said Pat Sloan, an Omnicom spokeswoman. Yet when the ad agency paid $20 million for part-ownership of Scirex in 1999, a top Omnicom executive, Thomas L. Harrison, said he expected Scirex's research to produce positive results for drug company clients - results that would help speed new-drug applications, or N.D.A.'s, to the F.D.A. "Our goal," he said, "is to help ensure that all clinical studies and each patient accrued into a study can be assessed to support the N. For more info regarding UK solicitor look into our web site. D.A.